107220-28-0

107220-28-0 structure

Name: Cevimeline hydrochloride
Chemical Name: 2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane],hydrochloride
CAS Number: 107220-28-0
Molecular Formula: C₁₀H₁₈ClNOS
Molecular Weight: 235.774
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2017-01-07 19:56:25
Modify Date: 2024-01-02 12:11:04
Cevimeline (Evoxac) Hcl is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.IC50 value:Target: M3 receptor

Name	2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane],hydrochloride
Synonyms	(2R,2'R)-2'-méthylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] chlorhydrate (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride (2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride (1:1) (2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octan-2,5'-[1,3]oxathiolan]hydrochlorid Cevimeline Hydrochloride Salt AF 102B hydrochloride Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-, hydrochloride (1:1) spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-, hydrochloride Cevimeline hydrochloride

Description	Cevimeline (Evoxac) Hcl is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.IC50 value:Target: M3 receptor
Related Catalog	Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Neurological Disease
References	[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9. [2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17. [3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14. [4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9. [5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.